March 19, 2026. More for You ...

Brain imaging offers a way to examine how different regions of the brain participate in cognitive function”— Dr.

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

Learn how smart collars and sensors track vitals to ensure a longer, healthier life, and discover how they provide real-time location and peace of mind.

AUSTIN, TX - March 19, 2026 - Published research in Molecular Psychiatry evaluating folinic acid supplementation in ...

Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead inve ...

MOH said it will provide an update when it is ready, with a decision expected to be made in 2026. Read more at ...

DM End-to-End uses AI to connect observation, treatment, and retention with a new cap fee for total cost transparency ...

The study also reported a 42% lower risk of psychiatric hospitalizations and work absences during periods when patients were taking semaglutide compared with periods when they were not.

Event-driven primary disease-free survival ('DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ('PDAC”) is anticipated in 1H 2026Fewer ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

Capital Infusion -- $15.9 million raised from Coastland Capital and Janus Henderson through a private placement, with a potential additional $15 million tranche contingent on milestone achievement.